Strategic Minority Investment Company MiNA Therapeutics Enters Into Collaboration & Licensing Agreement With Boehringer Ingel...
08 Novembre 2017 - 1:00PM
Business Wire
Sosei Group Corporation (‘Sosei’; TSE Mothers Index 4565), is
pleased to note that our strategic minority investment company MiNA
Therapeutics ('MiNA') has announced a collaboration and licensing
agreement with the global pharmaceutical company Boehringer
Ingelheim for the development of novel treatment approaches for
fibrotic liver diseases.
Under the terms of the agreement, MiNA will receive an upfront
payment and committed research funding as well as potential
research, development and regulatory milestone payments totaling up
to EUR 307 million. In addition, MiNA is entitled to double-digit
royalties on sales of selected products resulting from the
partnership. No further financial details were disclosed.
Commenting on the release, Peter Bains, CEO at Sosei, said: “We
are very encouraged by this agreement, which is MiNA’s first ever
major collaboration and reinforces its leading position in small
activating RNA (‘saRNA’) therapeutics. Furthermore, we believe it
represents a strong validation of the broad potential for its
proprietary technology.”
Click here for link to the full press release from MiNA
Therapeutics and Boehringer Ingelheim
About Sosei Group Corporation
Sosei Group Corporation is an international biopharmaceutical
company originating from Japan that discovers and develops
innovative biopharmaceuticals for the treatment of Alzheimer's
disease, schizophrenia, cancer, migraine, addiction, metabolic
disease, and other indications. By utilizing its GPCR
structure-based drug design platform technology, Sosei has
established a product pipeline with first/best in class potential.
Through development and commercialization partnerships, Sosei has
already delivered two bronchodilators for COPD which generate
significant and stable revenue streams that enable further growth.
Sosei partners include Novartis, Allergan, AstraZeneca, MedImmune,
MorphoSys, Teva, and Pfizer and we are actively looking for new
partnerships to enhance the development of our products and help us
deliver them to patients worldwide.
For further information about Sosei, please visit
http://www.sosei.com/en/.
Forward-looking statements
This press release contains forward-looking statements,
including statements about the discovery, development and
commercialisation of products. Various risks may cause Sosei’s
actual results to differ materially from those expressed or implied
by the forward-looking statements, including: adverse results in
clinical development programmes; failure to obtain patent
protection for inventions; commercial limitations imposed by
patents owned or controlled by third parties; dependence upon
strategic alliance partners to develop and commercialise products
and services; difficulties or delays in obtaining regulatory
approvals to market products and services resulting from
development efforts; the requirement for substantial funding to
conduct research and development and to expand commercialisation
activities; and product initiatives by competitors. As a result of
these factors, prospective investors are cautioned not to rely on
any forward-looking statements. We disclaim any intention or
obligation to update or revise any forward-looking statements,
whether as a result of new information, future events or
otherwise.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20171108005810/en/
Sosei Group CorporationChris Cargill,
+44-(0)7912-892-199Head of Investor Relations and Corporate
Communicationsccargill@sosei.comorHarumi Banse,
+81-(0)3-5210-3399Investor Relations and Corporate
Communicationshbanse@sosei.com